REGN Regeneron Pharmaceuticals Inc.

Regeneron Announces Investor Conference Presentations

Regeneron Announces Investor Conference Presentations

TARRYTOWN, N.Y., Oct. 25, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows:

  • BMO Biopharma Spotlight Series: Oncology at 9:30 a.m. ET on Wednesday, November 8, 2023
  • Truist Securities BioPharma Symposium at 3:20 p.m. ET on Wednesday, November 8, 2023
  • UBS Biopharma Conference at 11:00 a.m. ET on Thursday, November 9, 2023

  • Jefferies London Healthcare Conference at 2:30 p.m. GMT (9:30 a.m. ET) on Wednesday, November 15, 2023

The sessions may be accessed from the "Investors & Media" page of Regeneron's website at . Replays and transcripts of the webcasts will be archived on the Company's website for at least 30 days.

About Regeneron

Regeneron is a leading biotechnology company that invents, develops, and commercializes life-transforming medicines for people with serious diseases. Founded and led for 35 years by physician-scientists, Regeneron's unique ability to repeatedly and consistently translate science into medicine has led to numerous FDA-approved treatments and product candidates in development, almost all of which were homegrown in Regeneron's laboratories.

Regeneron's medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, hematologic conditions, infectious diseases, and rare diseases. 

Regeneron is accelerating and improving the traditional drug development process through its proprietary VelociSuite® technologies, such as VelocImmune®, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies, and through ambitious research initiatives such as the Regeneron Genetics Center®, which is conducting one of the largest genetics sequencing efforts in the world. 

For additional information about Regeneron, please visit  or follow Regeneron on .

Contact Information:

Investor Relations

Ryan Crowe

914.847.8790



EN
25/10/2023

Underlying

REGNRegeneron Pharmaceuticals Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Regeneron Pharmaceuticals Inc.

 PRESS RELEASE
Free
REGN Regeneron Pharm...

Regeneron Collaborates with TriNetX to Access De-Identified Electronic...

Regeneron Collaborates with TriNetX to Access De-Identified Electronic Health Records of 300 Million Patients to Drive Research and Product Development in Life Sciences and Digital Health Solutions Regeneron has exclusive opportunity to connect large-scale genomic and proteomic data cohorts to TriNetX’s industry-leading global network of electronic health record data Collaboration will expand Regeneron’s world-leading genomic and proteomic EHR-linked database Growing database will continue to drive drug discovery and development and empower AI training algorithms to deliver digital healt...

April 2, 2026 1 EN
 PRESS RELEASE
Free
REGN Regeneron Pharm...

EYLEA HD® (aflibercept) Approved by FDA as First and Only Injectable A...

EYLEA HD® (aflibercept) Approved by FDA as First and Only Injectable Anti-VEGF with Dosing Intervals Up to 5 Months for Wet Age-related Macular Degeneration (wAMD) and Diabetic Macular Edema (DME) Approval is based on 96-week data from 2 pivotal trials showing majority of EYLEA HD patients maintained their visual and anatomic improvements with extended dosing intervals New EYLEA HD dosing regimen allows patients with wAMD and DME to be treated as infrequently as 2 to 3 times a year, further extending the widest range of dosing intervals of any approved injectable anti-VEGF TARRYTOWN, N.Y...

April 2, 2026 1 EN
 PRESS RELEASE
Free
REGN Regeneron Pharm...

Regeneron to Report First Quarter 2026 Financial and Operating Results...

Regeneron to Report First Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast on April 29, 2026 TARRYTOWN, N.Y., March 25, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its first quarter 2026 financial and operating results on Wednesday, April 29, 2026, before the U.S. financial markets open. The Company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time that day. Conference Call Information Participants may access the conference call live via webcast on the ’Investors a...

March 25, 2026 1 EN
 PRESS RELEASE
Free
REGN Regeneron Pharm...

Dupixent® (dupilumab) Approved in Japan as the First Targeted Medicine...

Dupixent® (dupilumab) Approved in Japan as the First Targeted Medicine to Treat Adults with Bullous Pemphigoid (BP) Approval in moderate-to-severe patients was based on pivotal trial results showing over four times more Dupixent patients experienced sustained disease remission through Week 36 compared with placebo BP is a chronic, relapsing skin disease with underlying type 2 inflammation characterized by intense itch alongside painful blisters and other lesions BP is the seventh approved indication for Dupixent in Japan TARRYTOWN, N.Y. and PARIS, March 24, 2026 (GLOBE NEWSWIRE) -- Reg...

March 24, 2026 1 EN
 PRESS RELEASE
Free
REGN Regeneron Pharm...

Regeneron Science Talent Search 2026 Recognizes America’s Top Young Sc...

Regeneron Science Talent Search 2026 Recognizes America’s Top Young Scientists, Awarding More Than $1.8 Million to High School Seniors for Innovative Research in Computational Mathematics, Neural Science, and Blood Cancer Treatment $250,000 top award goes to Connor Hill in America’s longest running and most distinguished science and math competition TARRYTOWN, N.Y. and WASHINGTON, March 10, 2026 (GLOBE NEWSWIRE) -- (NASDAQ: REGN) and (the Society) announced that Connor Hill, 17, of State College, Pennsylvania, won the top award of $250,000 in the 2026 (STS), the U.S.’s oldest and mos...

March 11, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch